
CLAIMS

1. A compound which is a benzodiazepine derivative of formula (Ib):



(Ib)

wherein:


R^1 is H or halo;

Y is selected from O, S, SO, SO_2 and NR;

one or two of V, W and X is N or CH and the other one or two is or are CH;

R^2 is a group selected from C_1-C_6 alkyl, C_1-C_6 hydroxyalkyl, C_1-C_6 haloalkyl, halo, -OR, -NHR″, $-SO_mNR_2$, $-SO_mR$, nitro, $-CO_2R$, -CN, $-CONR_2$, -NHCOR and $–NR^{11}R^{12}$; each R is independently H or C_1-C_6 alkyl;

R^{11} and R^{12} are each independently H or C_1-C_6 alkyl; or R^{11} and R^{12} form, together with the N atom to which they are attached, either (a) a morpholine ring which is optionally bridged by a $-CH_2-$ group linking two ring carbon atoms that are positioned para to each other, or (b) a spiro group of the following formula (b):



(b);

R″ is C_3-C_6 cycloalkyl;

m is 1 or 2;

n is 0, 1 or 2; and

each of R^3 to R^{10} is independently selected from H, C_1-C_6 alkyl, halo, -OR, -NR_2, -NHR″, -SO_mNR_2, -SO_mR, nitro, -CO_2R, -CN, -CONR, -NHCOR, –$NR^{13}R^{14}$ wherein R^{13} and R^{14} form, together with the N atom to which they are attached, a morpholine ring, and the following options (i) to (iii):

(i) any two of R^3 to R^{10} that bond to the same carbon atom form a C_3-C_6 spiro ring;

(ii) any two of R^3 to R^{10} that bond to non-adjacent carbon atoms form a C_1-C_3 bridgehead group linking the carbon atoms to which they are bonded; and

(iii) any two of R^3 to R^{10} that bond to adjacent carbon atoms form, together with the carbon atoms to which they are bonded, a C_3-C_6 cycloalkyl group;

and wherein each alkyl group or moiety recited above is linear or branched;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 wherein, in formula (Ib):

R^1 is H or F;

Y is O, S or SO_2;

each of V and X is CH and W is N or CH;


R^2 is selected from C_1-C_6 alkyl, halo, -NR_2 and -NHR″, in which R and R″ are as defined in claim 1;

n is 0, 1 or 2; and

each of R^3 to R^{10} is independently selected from H, C_1-C_6 alkyl, halo and –$NR^{13}R^{14}$ wherein R^{13} and R^{14} form, together with the N atom to which they are attached, a morpholine ring; or


any two of R^3 to R^{10} that bond to the same carbon atom form a C_3-C_6 spiro ring and the rest of R^3 to R^{10} are H; or any two of R^3 to R^{10} that bond to non-adjacent carbon atoms form a C_1-C_3 bridgehead group linking the carbon atoms to which they are bonded and the rest of R^3 to R^{10} are H.

3. A compound according to claim 1 or 2 which is a benzodiazepine derivative of the following formula (I′):



(I′)

wherein each of R^1, Y and R^3 to R^{10} is as defined in claim 1 or 2 and Z is selected from the following structures:



in which R and R″ are as defined in claim 1;
or a pharmaceutically acceptable salt thereof.

4. A compound according to any one of claims 1 to 3 wherein R^3 to R^{10} take the following values:

- each of R^3 to R^{10} is H; or
- one or two of R^3 to R^{10} are C_1-C_3 alkyl, halo or $–NR^{13}R^{14}$ wherein R^{13} and R^{14} form, together with the N atom to which they are attached, a morpholine ring, and the rest of R^3 to R^{10} are H; or
- R^3 and R^{10} form a C_1 or C_2 bridgehead group linking the carbon atoms to which they are attached, and each of R^4 to R^9 is H.

5. A compound according to any one of the preceding claims wherein R^3 to R^{10} take the following values:

- each of R^3 to R^{10} is H; or
- one of R^3 and R^{10} is C_1-C_3 alkyl and the rest of R^3 to R^{10} are H; or
- each of R^3 to R^8 is H and each of R^9 and R^{10} is C_1-C_3 alkyl; or
- each of R^4 to R^9 is H and each of R^3 and R^{10} is C_1-C_3 alkyl; or
- each of R^3 to R^6, R^9 and R^{10} is H and each of R^7 and R^8 is halo; or
- one of R^7 and R^8 is $–NR^{13}R^{14}$ wherein R^{13} and R^{14} form, together with the N atom to which they are attached, a morpholine ring, and the rest of R^3 to R^{10} are H; or
- R^3 and R^{10} form a C_1 or C_2 bridgehead group linking the carbon atoms to which they are attached, and each of R^4 to R^9 is H.

6. A compound according to any one of the preceding claims wherein Y is O.

7. A compound according to any one of claims 1 and 3 to 6 wherein R^1 is H or F.

8. A compound according to claim 1 which is selected from:
N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-2-phenyl-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;
N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-2-(2-fluorophenyl)-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;
2-(5-Methylpyridin-3-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;
N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-2-(5-methylpyridin-3-yl)-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;
2-(2-Fluorophenyl)-5,5-dimethyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-7,8-dihydro-6H-pyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;
N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-2-(2-fluorophenyl)-5,5-dimethyl-7,8-dihydro-6H-pyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;
2-(2-Fluorophenyl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;
N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-2-phenyl-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;

2-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;

2-[6-(Ethylamino)-2-fluoropyridin-3-yl]-5-methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;

2-[6-(Ethylamino)-2-fluoropyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-5-methyl-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;

2-[2-Fluoro-6-(propan-2-ylamino)pyridin-3-yl]-5-methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;

N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-2-[2-fluoro-6-(propan-2-ylamino)pyridin-3-yl]-5-methyl-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;

2-(2-Fluorophenyl)-8-methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;

N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-2-(2-fluorophenyl)-8-methyl-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;

2-(2,4-Difluorophenyl)-5-methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;

2-(2,4-Difluorophenyl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-5-methyl-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;

2-(2-Fluorophenyl)-5-methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;

N-((S)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[b]azepin-3-yl)-2-(2-fluorophenyl)-5,6,7,8-tetrahydro-5,8-methanopyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;

N-[(3S)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-2-(2-fluorophenyl)-5H,6H,7H,8H-pyrazolo[3,2-b][1,3]thiazepine-3-carboxamide;

N-[(3S)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-2-(2-fluorophenyl)-4,4-dioxo-5H,6H,7H,8H-4λ^6-pyrazolo[3,2-b][1,3]thiazepine-3-carboxamide;

2-(6-Ethylpyridin-3-yl)-6,6-difluoro-N-[(3S)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-5H,6H,7H,8H-pyrazolo[3,2-b][1,3]oxazepine-3-carboxamide;

6,6-Difluoro-N-[(3S)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-2-{6-[(propan-2-yl)amino]pyridin-3-yl}-5H,6H,7H,8H-pyrazolo[3,2-b][1,3]oxazepine-3-carboxamide;

5-Ethyl-2-(2-fluorophenyl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;

5-Ethyl-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-2-(2-fluorophenyl)-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;

5-Ethyl-2-(6-methylpyridin-3-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;

5-Ethyl-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-2-(6-methylpyridin-3-yl)-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;

4-(6-Ethylpyridin-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-7-oxa-2,3-diazatricyclo[6.2.1.0^{2,6}]undeca-3,5-diene-5-carboxamide;

N-[(3S)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-4-{6-(propan-2-yl)amino]pyridin-3-yl}-7-oxa-2,3-diazatricyclo[6.2.1.0^{2,6}]undeca-3,5-diene-5-carboxamide;

6,6-Difluoro-N-[(3S)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-2-(2-fluorophenyl)-5H,6H,7H,8H-pyrazolo[3,2-b][1,3]oxazepine-3-carboxamide;

2-(2-Fluorophenyl)-6-morpholin-4-yl-N-[(3R)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;

4-(2-Fluoro-4-methylsulfonylphenyl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-7-oxa-2,3-diazatricyclo[6.2.1.02,6]undeca-3,5-diene-5-carboxamide;

(5R*)-2-[6-(ethylamino)-2-fluoropyridin-3-yl]-5-methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;

(5S*)-2-[6-(ethylamino)-2-fluoropyridin-3-yl]-5-methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;

(5R)-2-[6-(ethylamino)-2-fluoropyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-5-methyl-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;

(5S*)-2-[6-(ethylamino)-2-fluoropyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-5-methyl-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;

(5R*)-2-[2-fluoro-6-(propan-2-ylamino)pyridin-3-yl]-5-methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;

(5S*)-2-[2-fluoro-6-(propan-2-ylamino)pyridin-3-yl]-5-methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;

(5R*)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-2-[2-fluoro-6-(propan-2-ylamino)pyridin-3-yl]-5-methyl-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;

(5S*)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-2-[2-fluoro-6-(propan-2-ylamino)pyridin-3-yl]-5-methyl-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;

(8R*)-2-(2-Fluorophenyl)-8-methyl-N-(2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl)-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;

(8S*)-2-(2-Fluorophenyl)-8-methyl-N-(2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl)-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;

(8R*)-N-(9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl)-2-(2-fluorophenyl)-8-methyl-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;

(8S*)-N-(9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl)-2-(2-fluorophenyl)-8-methyl-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;

(5R*)-2-(2,4-difluorophenyl)-5-methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;

(5S*)-2-(2,4-difluorophenyl)-5-methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;
(5R*)-2-(2,4-difluorophenyl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-5-methyl-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;
(5S*)-2-(2,4-difluorophenyl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-5-methyl-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;
(1S*,8R*)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-4-(2-fluorophenyl)-7-oxa-2,3-diazatricyclo[6.2.1.$0^{2,6}$]undeca-3,5-diene-5-carboxamide;
(1R*,8S*)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-4-(2-fluorophenyl)-7-oxa-2,3-diazatricyclo[6.2.1.$0^{2,6}$]undeca-3,5-diene-5-carboxamide;
(5R*)-5-ethyl-2-(2-fluorophenyl)-N-[(3S)-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-5H,6H,7H,8H-pyrazolo[3,2-b][1,3]oxazepine-3-carboxamide;
(5S*)-5-ethyl-2-(2-fluorophenyl)-N-[(3S)-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-5H,6H,7H,8H-pyrazolo[3,2-b][1,3]oxazepine-3-carboxamide;
(5R*)-5-ethyl-2-(2-fluorophenyl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;
(5S*)-5-ethyl-2-(2-fluorophenyl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]-5,6,7,8-tetrahydropyrazolo[5,1-b][1,3]oxazepine-3-carboxamide;
(5R*)-5-ethyl-2-(6-methylpyridin-3-yl)-N-[(3S)-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-5H,6H,7H,8H-pyrazolo[3,2-b][1,3]oxazepine-3-carboxamide;
(5S*)-5-ethyl-2-(6-methylpyridin-3-yl)-N-[(3S)-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-5H,6H,7H,8H-pyrazolo[3,2-b][1,3]oxazepine-3-carboxamide;
(5R*)-5-ethyl-N-[(3S)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-2-(6-methylpyridin-3-yl)-5H,6H,7H,8H-pyrazolo[3,2-b][1,3]oxazepine-3-carboxamide;
(5S*)-5-ethyl-N-[(3S)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-2-(6-methylpyridin-3-yl)-5H,6H,7H,8H-pyrazolo[3,2-b][1,3]oxazepine-3-carboxamide;
(1S*,8R*)-4-(6-ethylpyridin-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-7-oxa-2,3-diazatricyclo[6.2.1.$0^{2,6}$]undeca-3,5-diene-5-carboxamide;

(1R*,8S*)-4-(6-ethylpyridin-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-7-oxa-2,3-diazatricyclo[6.2.1.$0^{2,6}$]undeca-3,5-diene-5-carboxamide;

(1S*,8R*)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-4-{6-[(propan-2-yl)amino]pyridin-3-yl}-7-oxa-2,3-diazatricyclo[6.2.1.$0^{2,6}$]undeca-3,5-diene-5-carboxamide;

(1R*,8S*)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-4-{6-[(propan-2-yl)amino]pyridin-3-yl}-7-oxa-2,3-diazatricyclo[6.2.1.$0^{2,6}$]undeca-3,5-diene-5-carboxamide;

and the pharmaceutically acceptable salts thereof.

9. A pharmaceutical composition which comprises a compound as defined in any one of claims 1 to 8 and a pharmaceutically acceptable carrier or diluent.

10. A compound as defined in any one of claims 1 to 8 for use in the treatment of the human or animal body by therapy.

11. A compound as defined in any one of claims 1 to 8 for use in the treatment or prevention of an RSV infection.

12. Use of a compound as defined in any one of claims 1 to 8 in the manufacture of a medicament for the treatment or prevention of an RSV infection

13. The use of claim 12, wherein an effective amount of the medicament is to be administered to a subject suffering from or susceptible to an RSV infection.

14. A product containing:

(a) a compound as defined in any one of claims 1 to 8; and

(b) one or more further therapeutic agents;

for simultaneous, separate or sequential use in the treatment of a subject suffering from or susceptible to an RSV infection.

15. A product according to claim 14, wherein the further therapeutic agent is:

(i) a RSV nucleocapsid(N)-protein inhibitor;

(ii) a protein inhibitor, such as one that inhibits the phosphoprotein (P) protein and/or large (L) protein;

(iii) an anti-RSV monoclonal antibody, such as an F-protein antibody;

(iv) an immunomodulating toll-like receptor compound;

(v) a respiratory virus anti-viral, such as an anti-influenza and/or anti-rhinovirus compound; and/or

(vi) an anti-inflammatory compound.